Abstract Objective To examine the changes in serum chromogranin A (CgA) and urotensin II (U II) levels in children with chronic heart failure (CHF) and their clinical significance. Methods A total of 58 children with CHF, among whom 17 had endocardial fibroelastosis (EFE) and 41 had dilated cardiomyopathy (DCM), were selected as CHF group, and 20 healthy children were selected as control group. Serum levels of CgA and U II were measured using enzyme-linked immunosorbent assay, and the level of N-terminal pro-brain natriuretic peptide (NT-proBNP) was determined by bi-directional lateral flow immunoassay. Ventricular remodeling indices were measured using echocardiography. The correlation between serum CgA and U II levels and ventricular remodeling was evaluated by Pearson correlation or Spearman's rank correlation analysis. Results There were no significant differences in serum CgA and NT-proBNP levels between children with grade II heart function and the control group (P > 0.05). However, the serum CgA and NT-proBNP levels gradually increased as the heart function grade increased, and were significantly higher in grade III and IV children compared to those in the control group (P < 0.05). U II levels were lower in children with grade II, III, or IV heart function than those in the control group (P < 0.05), and significantly decreased with the aggravation of CHF (P < 0.05). There were no significant differences in CgA and U II levels between patients with EFE and DCM (P > 0.05). Serum CgA concentration was positively correlated with left ventricular mass index (LVMI), NT-proBNP, and cardiac function classification (r=0.279, 0.649, and 0.778 respectively; P < 0.05), but was negatively correlated with left ventricular ejection fraction (LVEF), left ventricular fractional shortening (LVFS), and U II (r=-0.369, -0.322, and -0.718 respectively; P < 0.05). Serum U II concentration was negatively correlated with NT-proBNP and cardiac function classification (r=-0.472 and -0.591 respectively; P < 0.05), but was not correlated with LVMI, LVEF, and LVFS (P > 0.05). Conclusions CgA may play a role in ventricular remodeling in children with CHF. Serum CgA and U II may serve as a reference for the diagnosis and functional classification of heart failure.
CHENG Yao-Yao,AN Jin-Dou,FENG Song et al. Changes in serum chromogranin A and urotensin II levels in children with chronic heart failure[J]. CJCP, 2017, 19(3): 313-317.
CHENG Yao-Yao,AN Jin-Dou,FENG Song et al. Changes in serum chromogranin A and urotensin II levels in children with chronic heart failure[J]. CJCP, 2017, 19(3): 313-317.
Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method[J]. Circulation, 1977, 55(4):613-618.
[8]
李佳.嗜铬粒蛋白A研究进展[J].中华实用诊断与治疗志, 2012, 26(6):527-528.
[9]
Tota B, Angelone T, Cerra MC. The surging role of chromogranin A in cardiovascular homeostasis[J]. Front Chem, 2014, 2:64.
Steiner HJ, Weiler R, Ludescher C, et al. Chromogranins A and B are co-localized with atrial natriuretic peptides insecretory granules of rat heart[J]. J Histochemistry Cytochem, 1990, 38(6):845-850.
[12]
Pieroni M, Corti A, Tota B, et al. Myocardial production of chromogranin A in human heart:a new regulatory peptide of cardiac function[J]. European Heart J, 2007, 28(9):1117-1127.
[13]
Goelze JP, Alehaqen U, Flyvbjerg A, et al. Chromogranin A as a biomarker in cardiovascular disease[J]. Biomarkers Med, 2014, 8(1):133-140.
[14]
Pasqua T, Corti A, Gentile S, et al. Full-length human chromogranin-A cardioactivity:myocardial, coronary, and stimulus-induced processing evidence in normotensive and hypertensivemale rat hearts[J]. Endocrinology, 2013, 154(9):3353-3365.
[15]
Pearson D, Shively JE, Clark BR, et al. Urotensin II:a somatostatin-like peptidein the caudal neurosecretory system of fishes[J]. Proc Natl Acad Sci U S A, 1980, 77(8):5021-5024.
[16]
Prosser HCG, Leprince J, Vaudry H, et al. Cardiovascular effects of native and non-native urotensin II and urotensin II-related peptide on rat and salmon hearts[J]. Peptides, 2006, 27(12):3261-3268.
[17]
Ames RS, Sarau HM, Chambers JK, et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14[J]. Nature, 1999, 401(6750):282-286.
[18]
Matsushita M, Shichiri M, Imai T, et al. Co-expression of urotensin II anditsreceptor (GPR14) in human cardiovascular and renal tissues[J]. J Hypertens, 2001, 19(12):2185-2190.
[19]
Liu W, Han Q, Liu Q, et al. An investigation into the expression and mechanism of action of urotensin II in chronic pressure-overloaded rat hearts[J]. Mol Med Rep, 2015, 12(5):6626-6634.
Ratti S, Curnis F, Longhi R, et al. Structure-activity relationship of chromogranin A in cell adhesion. Identification of an adhesion site for fibroblasts and smooth muscle cells[J]. J Biolo Chem, 2000, 275(38):29257-29263.
